- Company
- AZ will withdraw its KRW 50 bil Forxiga from KOR mkt
- by Kim, Jin-Gu Dec 12, 2023 05:38am
- Forxiga (dapagliflozin), an SGLT-2 inhibitor class diabetes drug worth KRW 50 billion a year, will withdraw from the domestic market. According to industry sources on the 11th, AstraZeneca Korea recently made the decision to discontinue supply of Forxiga in Korea. However, the company will continue to supply its dapagliflozin and metfor
- Company
- Reimb at a halt for one-shot IRD drug Luxturna
- by Eo, Yun-Ho Dec 12, 2023 05:38am
- Reimbursement discussions for the one-shot retinal disease treatment Luxturna is being delayed in Korea. According to Dailypharm coverage, Novartis Korea failed to reach an agreement with the National Health Insurance Service on the drug price of uxturna (voretigene neparvovec) for inherited retinal dystrophy (IRD) within the 60-day dea
- Company
- Taked’a new CMV drug Livtencity passes DREC review in 1 yr
- by Eo, Yun-Ho Dec 11, 2023 05:02am
- The reimbursement adequacy evaluation for the cytomegalovirus (CMV) treatment ‘Livtencity’ has been completed in 1 year since the drug received approval in Korea. According to industry sources, Takeda Pharmaceuticals Korea submitted its reimbursement application for Liventity (maribavir) in Q3, and the agenda has passed the review of the
- Company
- Trulicity sales fall 30%...affected by supply shortage
- by Kim, Jin-Gu Dec 11, 2023 05:02am
- Sales of the GLP-1 receptor antagonist class treatment Trulicity had fallen 30% in 1 year. This is estimated to have been due to the prolonged domestic supply disruptions. Major insulin products that experienced sporadic supply shortages have experienced a sharp decrease in sales. In the case of Xultophy, its sales, which had surged to KRW 4.
- Company
- Double-dose Trelegy Ellipta in reimb process for asthma
- by Eo, Yun-Ho Dec 11, 2023 05:02am
- The double dose of Trelegy Ellipta, which was approved for asthma, not COPD, is making rapid progress for reimbursement listing in korea. According to the pharmaceutical industry, GSK Korea has recently started reimbursement pricing negotiations with the National Health Insurance Service for its Trelegy 200 Ellipta (fluticasone furoate
- Company
- Chong Kun Dang receives attention for its 'R&D potential'
- by Chon, Seung-Hyun Dec 8, 2023 05:28pm
- Chong Kun Dang Pharmaceutical (CKD Pharm) has reported over 10 billion won of its R&D costs as assets for the first time. The cost includes increased clinical trial costs for the commercialization of its biosimilars and incrementally modified drugs (IMD). The company has gained recognition for its R&D potential following a major technology expor
- Company
- Gardasil dominates HPV vaccine mkt in KOR
- by Kim, Jin-Gu Dec 8, 2023 05:55am
- The human papillomavirus (HPV) vaccines Gardasil and Gardasil 9 have established dominance in the cervical cancer vaccine market. As of Q3, their market share has reached 99.9%. Following the expanded vaccination age limit and increase in domestic supply price, the quarterly sales of these vaccines increased to 35.3 billion won. Gardasil 9’s
- Company
- Former Janssen Korea President Cherry Huang goes to China
- by Eo, Yun-Ho Dec 8, 2023 05:55am
- It has been confirmed that the position of President at Janssen Korea is currently vacant. According to Dailypharm's coverage, former CEO Cherry Huang recently left the company to serve as President of the Chinese subsidiary. As a result, Janssen Korea is now in the search for a new president. Since being appointed president in May 202
- Company
- Jemperli reimbursed as immunotherapy for endometrial cancer
- by Dec 8, 2023 05:55am
- A new immuno-oncology drug has been added to the sparse list of treatments available for endometrial cancer. GSK Korea succeeded in obtaining insurance reimbursement for its Jemperli in a year since obtaining approval in Korea in December last year. GSK Korea held a press conference on Sunday at Lotte Hotel Seoul to celebrate the launch
- Company
- JW Pharm Hemlibra's sales tops KRW 10 bil for the 1st time
- by Chon, Seung-Hyun Dec 7, 2023 05:47am
- Annual sales of JW Pharmaceutical's Hemlibra has surpassed the 10 billion won mark for the first time since its launch in Korea. The expanded reimbursement significantly boosted sales, by threefold. According to the pharmaceutical research agency IQVIA, Hemlibra's Q3 sales reached 6.8 billion won, a 261.3% increase from 1.9 billion won in th
